After finishing at $15.86 in the prior trading day, Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) closed at $15.75, down -0.69%. In other words, the price has decreased by -$0.11 from its previous closing price. On the day, 828111 shares were traded.
Ratios:
Our goal is to gain a better understanding of CPRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.68 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 14, 2024, initiated with a Buy rating and assigned the stock a target price of $27.
On March 07, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $23.
On December 21, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $30.Oppenheimer initiated its Outperform rating on December 21, 2023, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’23 when Harper Molly sold 14,000 shares for $14.39 per share. The transaction valued at 201,420 led to the insider holds 0 shares of the business.
Tierney David S sold 50,000 shares of CPRX for $666,250 on Dec 12 ’23. The Director now owns 333,541 shares after completing the transaction at $13.32 per share. On Dec 11 ’23, another insider, GRANDE ALICIA, who serves as the VP, Treasurer and CFO of the company, sold 60,000 shares for $13.76 each. As a result, the insider received 825,780 and left with 50,557 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 1.86B and an Enterprise Value of 1.72B. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.85, and their Forward P/E ratio for the next fiscal year is 10.36. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.66 while its Price-to-Book (P/B) ratio in mrq is 4.35. Its current Enterprise Value per Revenue stands at 4.32 whereas that against EBITDA is 14.38.
Stock Price History:
Over the past 52 weeks, CPRX has reached a high of $18.22, while it has fallen to a 52-week low of $11.09. The 50-Day Moving Average of the stock is 14.94, while the 200-Day Moving Average is calculated to be 13.90.
Shares Statistics:
The stock has traded on average 1.49M shares per day over the past 3-months and 1.39M shares per day over the last 10 days, according to various share statistics. A total of 107.12M shares are outstanding, with a floating share count of 99.84M. Insiders hold about 15.29% of the company’s shares, while institutions hold 64.98% stake in the company. Shares short for CPRX as of Feb 29, 2024 were 6.47M with a Short Ratio of 4.34, compared to 4.69M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.49% and a Short% of Float of 6.77%.
